Skip to main content
. 2013 May 15;38(10):2003–2010. doi: 10.1038/npp.2013.99

Figure 2.

Figure 2

Weekly urinalysis data for African-Americans based on rs678849 genotype. Patients were treated for opioid dependence with either methadone (a) or buprenorphine (b) for 24 weeks. Weekly urine drug screens were administered for the presence of opioids other than the one prescribed. The average percentage of opioid-positive urine tests during each week is provided for individuals with either the C/C genotype or the C/T and T/T genotypes, which were combined due to the low number of T/T patients (n=3). Time, age, gender, maximal dose, and treatment group were analyzed as covariates. (a) Methadone patients with the CC genotype (n=21) were less likely to have opioid-positive urine drug screens than patients with the C/T or T/T genotypes (n=15; RR=0.52, 95% CI=0.44–0.60, p=0.001). (b) Buprenorphine patients with the CC genotype (n=24) were more likely to have opioid-positive drug screens than patients with the C/T or T/T genotypes (n=17; RR=2.17, 95% CI=1.95–2.68, p=0.008).